This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Report of Seventy-Five Cases

WILLIAM H. BOND, M.D.; ROBERT J. ROHN, M.D.; RICHARD W. DYKE, M.D.; PAUL J. FOUTS, M.D.

AMA Arch Intern Med. 1953;91(5):602-617.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

KARNOFSKY and his associates first reported on the clinical use of triethylene melamine in April, 1951. They found that triethylene melamine, though similar to nitrogen mustard (methyl-bis[2-chloroethyl]amine or tris[2-chloroethyl]amine) in its pharmacological effects, did not result in as great an incidence of nausea and vomiting as was associated with the use of nitrogen mustard. They also found that when the parenteral dose of triethylene melamine was doubled and given orally it was equally effective.

We first employed triethylene melamine in the spring of 1950 and since that time have treated 75 patients with this drug, the majority of whom have suffered from leukemia or malignant lymphoma. Various reports have been made on the clinical use of triethylene melamine.¹ This is the report of our experience with this drug.

The number of patients treated; their diseases, and the response to therapy are briefly summarized in the accompanying Table. In all instances . . . [Full Text PDF of this Article]

Author Affiliations
INDIANAPOLIS

From the Departments of Medicine, Indiana University Medical Center and Indianapolis General Hospital.

Footnotes
The triethylene melamine used in this study was provided by Dr. J. M. Ruegsegger of Lederle Laboratories Division, American Cyanamid Company, Pearl River, N. Y.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?